Welcome to Santa Cruz Biotechnology!

Aurora Kinase/Cdk Inhibitor (CAS 443797-96-4)

(Based on popularity)

Synonym:JNJ-7706621, 4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide
Application:(JNJ-7706621) a cell-permeable, reversible, ATP-competitive kinase inhibitor
CAS Number:443797-96-4
Purity:≥97%
Molecular Weight:435.4
Molecular Formula:C15H12F2N6O3S CH3CN
Refer to Certificate of Analysis for lot specific data (including water content).
Set Currency

 Ordering Information
Product NameCatalog #UnitPriceQtyAddFavorites
Aurora Kinase/Cdk Inhibitor sc-203829 5 mg $440
Description
Aurora Kinase/Cdk inhibitor (JNJ-7706621) is a cell-permeable triazolylsulfonamido compound that acts as a reversible, ATP-competitive kinase inhibitor with selectivity towards ARKs (IC50 = 11 and 15 nM for ARK-1 (Aurora-A) and ARK-2 (Aurora-B), respectively) and Cdk's (IC50 = 9, 4, and 3 nM for Cdc2 (Cdk1)/B, Cdk2/A, and Cdk2/E, respectively). Aurora Kinase/Cdk Inhibitor displays antitumor properties (IC50 in the range of 112-514 nM against various human cancer cell lines).
Technical Information
Physical State:Solid
Solubility:Soluble in DMSO.
Storage:Store at 4° C
IC50:Aurora-A: IC50 = 11 nM; Aurora-B: IC50 = 15 nM; Cdk1/B: IC50 = 9 nM; Cdk2/A: IC50 = 4 nM; Cdk2/E: IC50 = 3 nM; cancer cell lines: IC50 = 112 - 514 nM (human)
Safety and Reference Information
PubChem CID:16760303
SMILES:CC#N.Nc1nc(Nc2ccc(cc2)S(=O)(=O)N)nn1C(=O)c1c(F)cccc1F
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
References
Emanuel, S., et al. 2005. Cancer Res. 65, 9038. Lin R., et al. 2005. J. Med. Chem. 4
SDS
Certificate of Analysis

Catalog Number

Lot Number

Related Product Categories